FREEHOLD, N.J., June 18, 2019 /PRNewswire/ -- Avalon GloboCare
Corp. (NASDAQ: AVCO), a leading global developer of cell-based
technologies and therapeutics, today announced that it expects to
be added to the Russell 3000® Index, based on a preliminary list of
additions posted June 7, 2019.
Final inclusion in the Russell 3000® Index will be determined
following completion of the annual Russell US Indexes
Reconstitution, which occurs after the US equity markets close on
Friday, June 28, 2019.
Indexes provided by FTSE Russell, a leading global index
provider, are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment
strategies. Approximately $9
trillion in assets are benchmarked against the Russell US
Indexes. Membership in the Russell Microcap Index remains in place
for one year and provides for automatic inclusion in the
appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by
objective, market-capitalization rankings and style attributes.
"We look forward to our inclusion in the Russell 3000® Index,
which we believe reflects our continued growth and the progress we
are making at Avalon," stated David
Jin, M.D., Ph.D., CEO and President of Avalon
GloboCare. "Inclusion in the Russell 3000® Index is expected
to benefit our Company and shareholders by elevating our exposure
within the global investment community."
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech
bio-developer dedicated to advancing and empowering innovative,
transformative exosome technologies and cellular therapeutics.
Avalon also provides strategic advisory and outsourcing services to
facilitate and enhance its clients' growth, development, as well as
competitiveness in both the domestic and global healthcare markets.
Through its subsidiaries, namely GenExosome Technologies Inc. and
Avactis Biosciences Inc., Avalon is establishing a leading role in
the fields of exosome-based diagnostics (''liquid biopsy''),
cellular immunotherapy (including CAR-T/CAR-NK), and regenerative
medicine.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$16 trillion is currently benchmarked
to FTSE Russell indexes. For over 30 years, leading asset owners,
asset managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking
statements provide current expectations of future events based on
certain assumptions and include any statement that does not
directly relate to any historical or current fact. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors as disclosed in
our filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
View original
content:http://www.prnewswire.com/news-releases/avalon-globocare-expected-to-join-the-russell-3000-index-300870152.html
SOURCE Avalon GloboCare Corp.